Drug intelligence / Profile preview

YZ007

Development stage: Preclinical
Lead developer: Guangdong Yinzhu Pharmaceutical Technology
Modality: Small Molecules

Overview

YZ007 is a preclinical-stage small molecule inhibitor of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, currently under development by Guangdong Yinzhu Pharmaceutical Technology. The drug is designed to address pathologies where NF-κB is constitutively active or dysregulated, including various types of cancer (tumors) and autoimmune disorders. By inhibiting NF-κB, YZ007 aims to suppress the transcription of pro-inflammatory cytokines and anti-apoptotic genes, thereby inducing tumor cell death and reducing pathological inflammation.

Targets

NF-κB

Beyond the preview

Go deeper on YZ007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZ007.

Explore the full profile